Core Viewpoint - The domestic high-value medical consumables market is undergoing significant changes due to centralized procurement, with domestic companies expected to capture approximately 70% of the mainstream market in the coming years [1][2]. Group 1: Market Dynamics - The sixth batch of national centralized procurement for high-value medical consumables was announced, with 202 companies and 440 products winning bids, indicating a shift towards domestic brands [1]. - Since the implementation of centralized procurement in 2020, the market share of imported brands, which previously dominated over 90%, has been continuously eroded, leading to significant price reductions in products like coronary stents and drug-coated balloons [1][2]. - The average price of joint bone cement dropped by 83.13% due to centralized procurement, significantly reducing the financial burden on patients [2]. Group 2: Competitive Landscape - Domestic companies face a more severe challenge in the medical device sector compared to pharmaceuticals, as the technological gap between domestic products and imported brands is more pronounced [2]. - The centralized procurement model has created a dual-edged sword for domestic companies, allowing them to gain market access while also compressing profit margins due to intense price competition [2][3]. Group 3: Company Performance - Guichuang Tongqiao has actively embraced centralized procurement, resulting in a compound annual growth rate of 50-60% in performance after its products were included in procurement lists [3]. - The company has successfully maintained a gross margin of 71.6% in 2024, only slightly down from 2023, indicating resilience against price pressures [4]. Group 4: Future Outlook - The market for neuro-interventional consumables is expected to slow down after rapid growth, while the peripheral vascular business is projected to maintain a steady growth rate of around 40% [5]. - The company recognizes the need to enhance product quality and build trust among clinicians to facilitate the adoption of domestic brands [5]. Group 5: International Expansion - The international market for medical devices is significantly larger than the domestic market, making global expansion a necessity for companies like Guichuang Tongqiao [6][8]. - The company has entered into an agreement to acquire a stake in the German medical technology company Optimed, aiming to leverage its established R&D and commercialization platform in Europe [8][9]. - Innovation is deemed essential for gaining recognition in mainstream international markets, with the company focusing on both mergers and innovative product development to enhance its global presence [9].

Core Viewpoint - The recent announcement of the sixth batch of high-value medical consumables procurement in China indicates a significant shift towards domestic brands, with industry experts predicting that leading domestic companies will capture approximately 70% of the mainstream market [2]. Group 1: Market Dynamics - Since the implementation of high-value consumables procurement in 2020, the process of domestic substitution has accelerated, with imported brands previously dominating over 90% of the market share being increasingly challenged [2]. - The average price of coronary stents has dropped to around 1,000 yuan, and drug-coated balloon prices have also fallen to similar levels, significantly reducing surgical costs [2]. - By 2024, the market share of domestic neurointerventional products has risen to 26%, reshaping the competitive landscape [5]. Group 2: Company Performance - Guichuang Tongqiao has successfully embraced procurement, resulting in a compound annual growth rate of 56% in performance after its products were included in the procurement list [4]. - The company has maintained a gross margin of 71.6% in 2024, only slightly down by 1.3 percentage points from 2023, indicating resilience against price pressures [5]. - Guichuang Tongqiao's products have achieved significant market penetration, with certain products like the capture device leading in market share in Hebei [5]. Group 3: Challenges and Opportunities - Despite the rapid growth of domestic medical devices, there remains a notable gap in innovation capabilities compared to foreign counterparts, with many domestic products lacking substantial intellectual property [2][3]. - The procurement model has created a dual-edged sword for domestic companies, providing opportunities for market access while also compressing profit margins due to intense price competition [3]. - The company recognizes the need to build trust with clinicians, who are often accustomed to using imported products, emphasizing the importance of product quality and user education [6]. Group 4: International Expansion - The international market presents a significant opportunity for domestic medical device companies, with Guichuang Tongqiao already entering over 80 countries and regions [9]. - The company plans to expand its global footprint through acquisitions, such as the agreement with Optimed Medizinische Instrumente GmbH, to leverage established R&D and commercialization platforms in Europe [9]. - Innovation remains crucial for gaining recognition in mainstream markets, with the company acknowledging the longer timelines required for medical device innovation compared to pharmaceuticals [10].

根据《证券期货投资者适当性管理办法》及配套指引，本资料仅面向华创证券客户中的金融机构专业投资者，请勿对本资料进行任何形式的转发。若您不是华创证券客户中的金融机构专业投资者，请勿订 阅、接收或使用本资料中的信息。 本资料难以设置访问权限，若给您造成不便，敬请谅解。感谢您的理解与配合。 摘要 神经+外周介入双引擎驱动，受益集采，布局海外。 公司在神经介入、外周介入产品线布局全面，截止2025/3/20，公司共战略布局66款产品及候选产 品，已在国内商业化产品共计47款。公司抓住集采机遇，推动产品放量，实现收入的强劲增长，2021-2024年收入CAGR达到131%，并在2024年实现扭 亏为盈，全年净利润为1亿元，截至2024年底，账上资金总额达到25亿元，充裕现金流为产品管线自研/并购、商业化拓展提供支持。2024年海外收入 2258万元，同比增长58.2%，海外拓展已初具规模，有望为公司贡献长期业绩增量。 神经 介入：渗透率、国产化率双 低赛道，公司以丰富产品组合拥抱集采 。 1）行业：渗透率、国产化率双低的高潜力赛道。 国内神介手术受众群体大，近些年手术渗透率快速提升，神经介入耗材市场规模同步快速增长，20 ...

Core Viewpoint - The company is leveraging dual engines of neuro and peripheral intervention, benefiting from centralized procurement and expanding overseas, with a projected revenue CAGR of 131% from 2021 to 2024, and a turnaround to profitability in 2024 with a net profit of 100 million yuan [2][15]. Group 1: Company Overview - The company, established in 2012, focuses on innovative research, manufacturing, and sales of medical devices in neuro and peripheral vascular intervention [3]. - It has developed a comprehensive product line covering all five categories of neurovascular intervention and a full range of peripheral vascular intervention products, positioning itself in the top tier of the domestic market [5]. Group 2: Market Potential and Growth - The neuro intervention market in China has low penetration and localization rates, with a 2023 penetration rate of 13.8% for hemorrhagic neuro intervention surgeries, compared to 65.3% in the US, indicating significant growth potential [30][39]. - The domestic neuro intervention consumables market has grown rapidly, with a CAGR of 16% from 2017 to 2022, reaching 6.68 billion yuan [37]. Group 3: Centralized Procurement Impact - Since 2021, centralized procurement has expanded in the neuro intervention sector, benefiting leading domestic manufacturers by increasing market penetration and localization rates [43]. - The average price reduction from centralized procurement has stimulated demand, leading to increased sales volumes that offset some of the negative impacts of price drops [45]. Group 4: Financial Performance - The company achieved a revenue of 783 million yuan in 2024, with a year-on-year growth of 48%, and a net profit of 100 million yuan, marking a return to profitability [15]. - The gross margin has remained relatively stable at 71.6% despite some price reductions due to centralized procurement, supported by improved operational efficiency and a decrease in expense ratios [18]. Group 5: Overseas Expansion - In 2024, the company generated 22.58 million yuan in overseas revenue, a 58.2% increase, with plans to expand into Europe and emerging markets in Asia, Africa, and Latin America [24]. - The company has already commercialized 20 products in 24 overseas countries, with 8 products receiving CE marks in Europe [29]. Group 6: Product Pipeline and Innovation - The company has a robust product pipeline with 66 strategic products and candidates, of which 47 are already commercialized, and expects 17 more to be approved between 2025 and 2027 [5][49]. - Upcoming products include a flow-directed stent and a drug-eluting self-expanding intracranial stent, which are anticipated to significantly contribute to revenue growth [52][53].